BioLife Solutions, Inc. $BLFS Shares Sold by Casdin Capital LLC

Casdin Capital LLC trimmed its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 11.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,957,165 shares of the medical equipment provider’s stock after selling 750,000 shares during the period. BioLife Solutions accounts for about 8.9% of Casdin Capital LLC’s holdings, making the stock its 3rd biggest holding. Casdin Capital LLC owned approximately 12.37% of BioLife Solutions worth $144,044,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Global Retirement Partners LLC purchased a new stake in shares of BioLife Solutions in the 4th quarter valued at approximately $30,000. Kemnay Advisory Services Inc. acquired a new stake in BioLife Solutions in the 4th quarter worth $35,000. Quarry LP lifted its holdings in shares of BioLife Solutions by 50.9% during the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after acquiring an additional 713 shares during the period. Hantz Financial Services Inc. lifted its holdings in shares of BioLife Solutions by 42.4% during the 4th quarter. Hantz Financial Services Inc. now owns 2,673 shares of the medical equipment provider’s stock worth $65,000 after acquiring an additional 796 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in BioLife Solutions by 82.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,425 shares of the medical equipment provider’s stock valued at $113,000 after purchasing an additional 1,994 shares during the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BLFS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research note on Monday, April 20th. Wall Street Zen upgraded shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Zacks Research cut shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 12th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $32.00.

Insider Transactions at BioLife Solutions

In other news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $23.70, for a total value of $15,405,000.00. Following the completion of the sale, the insider owned 4,757,165 shares in the company, valued at $112,744,810.50. This represents a 12.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders sold 1,200,000 shares of company stock valued at $28,125,000. Corporate insiders own 2.20% of the company’s stock.

BioLife Solutions Price Performance

Shares of BLFS opened at $25.58 on Thursday. The business’s 50 day simple moving average is $23.17 and its 200-day simple moving average is $22.95. BioLife Solutions, Inc. has a 1 year low of $17.86 and a 1 year high of $29.62. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -319.71 and a beta of 2.00.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Thursday, May 7th. The medical equipment provider reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. The company had revenue of $27.50 million for the quarter, compared to the consensus estimate of $25.66 million. BioLife Solutions had a positive return on equity of 1.81% and a negative net margin of 2.80%. On average, sell-side analysts expect that BioLife Solutions, Inc. will post 0.07 earnings per share for the current year.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.